New Lung Cancer Drug Works in Trial

Tuesday, 13 Aug 2013 12:06 PM

 

Share:
  Comment  |
   Contact Us  |
  Print  
|  A   A  
  Copy Shortlink

Eli Lilly and Co said its experimental lung cancer drug increased survival of patients in a late-stage trial, and the company plans to file for a U.S. marketing application before the end of 2014.
Lilly shares were up 4 percent in premarket trading.
The drug, necitumumab or IMC-11F8, was given to patients with advanced non-small cell lung cancer in combination with already-approved chemotherapy drug gemcitabine and cisplatin, and was compared with chemotherapy alone.
"If approved, necitumumab could be the first biologic therapy indicated to treat patients with squamous lung cancer," Richard Gaynor, Lilly's vice president for product development and medical affairs, said in a statement.
The company's stock closed at $54.05 on the New York Stock Exchange on Monday.

© 2014 Thomson/Reuters. All rights reserved.

Share:
  Comment  |
   Contact Us  |
  Print  
  Copy Shortlink
Around the Web
Join the Newsmax Community
Please review Community Guidelines before posting a comment.
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
 
Email:
Country
Zip Code:
Privacy: We never share your email.
 
Hot Topics
Follow Newsmax
Like us
on Facebook
Follow us
on Twitter
Add us
on Google Plus
Around the Web
Top Stories
You May Also Like

Hospitals Gird for Ebola Panic as Flu Season Looms

Sunday, 19 Oct 2014 09:39 AM

A young woman complaining of abdominal pain and nausea who had traveled to Africa arrived at a Long Island hospital fear . . .

Vitamin D Found to Ease Eczema

Saturday, 18 Oct 2014 09:32 AM

Daily vitamin D supplements might help children with eczema that gets worse in the winter, a new study suggests. When ec . . .

Way You Walk Affects Mood: Study

Saturday, 18 Oct 2014 09:25 AM

The way you walk can affect your mood, according to a new study.
Previous research has shown that depressed people  . . .

Most Commented

Newsmax, Moneynews, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, NewsmaxWorld, NewsmaxHealth, are trademarks of Newsmax Media, Inc.

 
NEWSMAX.COM
America's News Page
©  Newsmax Media, Inc.
All Rights Reserved